Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.52 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | STK25 | O00506 | 1/20 | 0.42 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | CASK | O14936 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878183 | 0.90 | MEN1 (0.57) | SRCMTORSMG1CDK1CDK2 | |
| SCHEMBL3459265 | 0.79 | JAK2 (0.52) | SRCMTORSMG1CDK1CDK2 | |
| SCHEMBL14024423 | 0.78 | JAK3 (0.49) | SRCCDK2JAK2JAK3SYK | |
| SCHEMBL30023485 | 0.76 | FEN1 (0.44) | MTORSMG1CDK1CDK2SYK | |
| SCHEMBL14024530 | 0.76 | KDR (0.59) | SRCJAK2JAK3BRD4SYK | |
| SCHEMBL2877375 | 0.74 | MEN1 (0.71) | EPHX2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL4880015 | 0.73 | AIMP2 (0.57) | SRCYES1PDGFRBAXLHRH3 | |
| SCHEMBL13091569 | 0.72 | MEN1 (0.49) | KCNH2HRH3MEN1KMT2AALDH1A1 | |
| SCHEMBL14476103 | 0.72 | MEN1 (0.73) | SLC6A3MEN1KMT2AALDH1A1POLB | |
| SCHEMBL30557958 | 0.71 | ROCK1 (0.61) | SRCMTORSMG1CDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| EP-2154967-A1 | PYRIMIDINE DERIVATIVES | Hutchison Medipharma Enterprises Limited (BS) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | SRC 4249/4885MTOR 1373/4885SMG1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.